{"id":337912,"date":"2025-08-19T13:11:03","date_gmt":"2025-08-19T13:11:03","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-abbvie\/"},"modified":"2025-08-19T13:11:03","modified_gmt":"2025-08-19T13:11:03","slug":"how-to-buy-abbvie","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/","title":{"rendered":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-337912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"\u0130la\u00e7 sekt\u00f6r\u00fc f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, 2025 tahminleri ve ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile AbbVie Inc. (ABBV) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"\u0130la\u00e7 sekt\u00f6r\u00fc f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, 2025 tahminleri ve ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile AbbVie Inc. (ABBV) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"D\u00fcnyan\u0131n en b\u00fcy\u00fck ila\u00e7 devlerinden birinin bir par\u00e7as\u0131na sahip olmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AbbVie Inc. (ABBV), sa\u011fl\u0131k sekt\u00f6r\u00fcnde istikrar ile yenili\u011fin bulu\u015ftu\u011fu bir \u015firket olup, hem yeni hem de deneyimli yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmeldir. Skyrizi ve Rinvoq gibi blockbuster ila\u00e7lar Humira d\u00f6neminin \u00f6tesinde b\u00fcy\u00fcmeyi s\u00fcrd\u00fcr\u00fcrken, bu \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131n hayat\u0131na dokunuyor. Size her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z: mevcut hisse performans\u0131, stratejik giri\u015f noktalar\u0131 ve 2025'in geli\u015fen ila\u00e7 sekt\u00f6r\u00fcnde neden benzersiz yat\u0131r\u0131m f\u0131rsatlar\u0131 sundu\u011fu.","intro_source":{"label":"Intro","type":"text","formatted_value":"D\u00fcnyan\u0131n en b\u00fcy\u00fck ila\u00e7 devlerinden birinin bir par\u00e7as\u0131na sahip olmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AbbVie Inc. (ABBV), sa\u011fl\u0131k sekt\u00f6r\u00fcnde istikrar ile yenili\u011fin bulu\u015ftu\u011fu bir \u015firket olup, hem yeni hem de deneyimli yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmeldir. Skyrizi ve Rinvoq gibi blockbuster ila\u00e7lar Humira d\u00f6neminin \u00f6tesinde b\u00fcy\u00fcmeyi s\u00fcrd\u00fcr\u00fcrken, bu \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131n hayat\u0131na dokunuyor. Size her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z: mevcut hisse performans\u0131, stratejik giri\u015f noktalar\u0131 ve 2025'in geli\u015fen ila\u00e7 sekt\u00f6r\u00fcnde neden benzersiz yat\u0131r\u0131m f\u0131rsatlar\u0131 sundu\u011fu."},"body_html":"<h2>\ud83d\udcc8 AbbVie Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla, AbbVie Inc. (ABBV) New York Borsas\u0131'nda <strong>206,57 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>29 Ekim 2025<\/strong> kesinlikle kritik bir tarih\u2014AbbVie'nin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketleri yarat\u0131r ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bundan faydalanabilir.<\/p> <p><strong>Kazan\u00e7 Raporlar\u0131 ABBV Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>31 Temmuz 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>208,40 $<\/td><td>%3,2 Art\u0131\u015f (1 hafta)<\/td><\/tr> <tr><td>25 Nisan 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>195,80 $<\/td><td>%6,8 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>31 Ocak 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>182,50 $<\/td><td>%7,1 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td><\/tr> <tr><td>29 Ekim 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>175,20 $<\/td><td>%2,3 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7t\u0131)<\/td><\/tr> <tr><td>26 Temmuz 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>168,90 $<\/td><td>%4,9 Art\u0131\u015f (Skyrizi patlamas\u0131)<\/td><\/tr> <tr><td>26 Nisan 2024<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>162,10 $<\/td><td>%3,8 Art\u0131\u015f (istikrarl\u0131 b\u00fcy\u00fcme)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Temmuz 2025 gibi pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 birka\u00e7 g\u00fcn i\u00e7inde %3-7 oran\u0131nda art\u0131r\u0131r. Negatif sonu\u00e7lar bile, AbbVie'nin g\u00fc\u00e7l\u00fc temelleri sayesinde h\u0131zl\u0131 toparlanma f\u0131rsatlar\u0131 yarat\u0131r.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2> <p>AbbVie hisseleri genel olarak yukar\u0131 y\u00f6nl\u00fc etkileyici bir diren\u00e7 g\u00f6sterdi:<\/p> <ul> <li><strong>Mart 2025<\/strong>: 249 $ (k\u0131\u015f sonras\u0131 toparlanma +%6,9)<\/li> <li><strong>Nisan 2025<\/strong>: 263 $ (1. \u00e7eyrek kazan\u00e7 ivmesi +%5,6)<\/li> <li><strong>May\u0131s 2025<\/strong>: 268 $ (\u00fcretim geni\u015fleme haberi +%1,9)<\/li> <li><strong>Haziran 2025<\/strong>: 280 $ (pipeline geli\u015fmeleri +%4,5)<\/li> <li><strong>Temmuz 2025<\/strong>: 316 $ (2. \u00e7eyrek kazan\u00e7 patlamas\u0131 +%12,9)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 276 $ (kar realizasyonu d\u00fczeltmesi -%12,7)<\/li> <\/ul> <p><strong>Bu ola\u011fan\u00fcst\u00fc performans\u0131n sebebi nedir?<\/strong> Skyrizi ve Rinvoq, 2025 1. \u00e7eyre\u011finde toplam 5,1 milyar $ sat\u0131\u015f ger\u00e7ekle\u015ftirdi\u2014y\u0131ll\u0131k %65 b\u00fcy\u00fcme. \u015eirketin stratejik 195 milyon $ \u00fcretim yat\u0131r\u0131m\u0131 ve ba\u015far\u0131l\u0131 klinik deneme sonu\u00e7lar\u0131 bu d\u00f6nemde yat\u0131r\u0131mc\u0131 g\u00fcvenini s\u00fcrd\u00fcr\u00fclebilir k\u0131ld\u0131.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 215-250 $ (g\u00fc\u00e7l\u00fc tatil \u00e7eyre\u011fi + pipeline kilometre ta\u015flar\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li> <li><strong>2026 Projeksiyonu<\/strong>: 230-270 $ (uluslararas\u0131 geni\u015fleme + yeni endikasyonlar)<\/li> <li><strong>2028 Hedefi<\/strong>: 270-310 $ (terap\u00f6tik alan hakimiyeti + pazar pay\u0131 kazan\u0131mlar\u0131)<\/li> <li><strong>2030 Vizyonu<\/strong>: 310-370 $ (k\u00fcresel sa\u011fl\u0131k b\u00fcy\u00fcmesi + yenilik liderli\u011fi)<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: <strong>Uzun vadeli birikim<\/strong> i\u00e7in ideal. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar 29 Ekim civar\u0131ndaki kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri izlemeli.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Humira Biyobenzeri Bask\u0131s\u0131<\/strong>: Patent korumas\u0131n\u0131n sona ermesiyle 2024 ba\u015f\u0131nda sat\u0131\u015flar %41 d\u00fc\u015ft\u00fc (<a href=\"https:\/\/monexa.ai\/blog\/abbvie-abbv-acquisition-expenses-humira-challenges-ABBV-2025-04-04\">Rekabet Etkisi<\/a>)<\/li> <li><strong>Reg\u00fclasyon Zorluklar\u0131<\/strong>: 2025 2. \u00e7eyrekte 29 finansal ve kurumsal risk tespit edildi, Ar-Ge belirsizlikleri ve uluslararas\u0131 operasyon karma\u015f\u0131kl\u0131klar\u0131 dahil<\/li> <li><strong>D\u00f6viz Dalgalanmas\u0131<\/strong>: Gelirin %24'\u00fc ABD d\u0131\u015f\u0131ndan geliyor, bu da k\u00e2rlar\u0131 d\u00f6viz kuru dalgalanmalar\u0131na kar\u015f\u0131 hassas k\u0131l\u0131yor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Skyrizi\/Rinvoq Roket Yak\u0131t\u0131<\/strong>: 2025'te 24,7 milyar $ ve 2027'de 31 milyar $ sat\u0131\u015f bekleniyor (<a href=\"https:\/\/www.nasdaq.com\/articles\/abbvie-stock-down-around-13-3-months-time-buy-dip\">B\u00fcy\u00fcme Projeksiyonlar\u0131<\/a>)<\/li> <li><strong>\u00dcretim Geni\u015flemesi<\/strong>: API \u00fcretim kapasitesini art\u0131ran 195 milyon $ yat\u0131r\u0131m (<a href=\"https:\/\/www.ainvest.com\/news\/abbvie-195m-illinois-expansion-drives-10b-investment-plan-182nd-tier-trading-volume-2508\/\">Stratejik Yat\u0131r\u0131m<\/a>)<\/li> <li><strong>Klinik At\u0131l\u0131mlar<\/strong>: Faz 3 denemesi kanser ilerleme riskini %79 azaltt\u0131<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ul> <li><strong>Stratejik Birikim<\/strong>: Haftal\u0131k sadece 100 $ gibi k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n\u2014zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in dolar maliyeti ortalamas\u0131 kullan\u0131n<\/li> <li><strong>Kazan\u00e7 Takibi<\/strong>: 29 Ekim kazan\u00e7lar\u0131 i\u00e7in uyar\u0131lar kurun; a\u00e7\u0131klama sonras\u0131 hisse %3-5 d\u00fc\u015ferse almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Portf\u00f6y Dengesi<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn maksimum %8-10'unu ABBV gibi ila\u00e7 hisselerine ay\u0131r\u0131n<\/li> <li><strong>Esprili deneyimli tavsiyesi<\/strong>: \"ABBV ticareti, ila\u00e7 Ar-Ge'si gibidir\u2014bazen uzun vadeli sa\u011fl\u0131k faydalar\u0131 i\u00e7in k\u0131sa vadeli yan etkileri g\u00f6ze almal\u0131s\u0131n\u0131z. Piyasay\u0131 deneysel ila\u00e7 al\u0131r gibi zamanlamaya \u00e7al\u0131\u015fmay\u0131n!\"<\/li> <\/ul>  <h2>\u2705 AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ticaret platformu se\u00e7in<\/td><td>NYSE eri\u015fimi ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014k\u0131smi hisseler i\u00e7in 50 $ bile yeterli<\/td><\/tr> <tr><td>3<\/td><td>\"ABBV\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>Sadece \"AbbVie\" de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emri: \u00d6deyece\u011finiz maksimum fiyat\u0131 belirleyin (\u00f6rne\u011fin 208 $)<\/td><\/tr> <tr><td>5<\/td><td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td><td>Komisyon maliyetlerini g\u00f6zden ge\u00e7irin\u2014i\u015flem \u00fccretlerinin %0,5'in alt\u0131nda olmas\u0131na dikkat edin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonu izleyin<\/td><td>Kazan\u00e7 tarihleri ve \u00f6nemli haberler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>7<\/td><td>Temett\u00fcleri yeniden yat\u0131r\u0131n<\/td><td>ABBV y\u0131lda 6,56 $ \u00f6der\u2014bile\u015fik getiri i\u00e7in DRIP'i etkinle\u015ftirin<\/td><\/tr> <tr><td>8<\/td><td>\u00c7eyrek d\u00f6nemlerde g\u00f6zden ge\u00e7irin<\/td><td>Performans\u0131 ila\u00e7 sekt\u00f6r\u00fc k\u0131yaslamalar\u0131na kar\u015f\u0131 de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in borsa eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri neredeyse hi\u00e7 finansal risk olmadan test edin<\/li> <li><strong>60 saniyede do\u011frulama<\/strong>\u2014herhangi bir resmi kimlik y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li> <li><strong>100'den fazla para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para, e-c\u00fczdanlar, banka transferleri, kredi kartlar\u0131<\/li> <li><strong>K\u0131smi hisse al\u0131m\u0131 m\u00fcmk\u00fcn<\/strong>\u2014ABBV gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 k\u00fc\u00e7\u00fck miktarlarla sat\u0131n al\u0131n<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014profesyonel grafikler ve analiz ara\u00e7lar\u0131na eri\u015fim<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, <strong>AbbVie Inc. (ABBV) hisse senedi yat\u0131r\u0131m\u0131n\u0131z\u0131<\/strong> kolayca ger\u00e7ekle\u015ftirmenizi sa\u011flarken, e\u011fitim kaynaklar\u0131 ila\u00e7 sekt\u00f6r\u00fc dinamiklerini anlaman\u0131za yard\u0131mc\u0131 olur.<\/p>  <h2>\ud83c\udf0d 2025'te AbbVie: \u0130la\u00e7 Devi D\u00f6n\u00fc\u015f\u00fcm\u00fc<\/h2> <p>AbbVie, Humira sonras\u0131 d\u00f6nemde ba\u011f\u0131\u015f\u0131kl\u0131k ve onkoloji pazarlar\u0131nda etkileyici bir d\u00f6n\u00fc\u015f\u00fcm hikayesiyle hakimiyet kuruyor. \u015eirket, bir\u00e7ok ila\u00e7 devini bat\u0131ran patent u\u00e7urumunu ba\u015far\u0131yla atlatt\u0131 ve 2025 2. \u00e7eyre\u011finde 15,42 milyar $ gelir elde eden \u00e7e\u015fitlendirilmi\u015f bir portf\u00f6yle g\u00fc\u00e7lenerek \u00e7\u0131kt\u0131.<\/p> <p><strong>Mevcut Pazar Konumu<\/strong>:<\/p> <ul> <li>Piyasa de\u011feri: 365,13 milyar $<\/li> <li>Temett\u00fc aristokrat\u0131: 11 y\u0131l \u00fcst \u00fcste art\u0131\u015f<\/li> <li>Ba\u011f\u0131\u015f\u0131kl\u0131k lideri: Skyrizi ile biyolojik sedef hastal\u0131\u011f\u0131 pazar\u0131nda %40 pay<\/li> <li>K\u00fcresel eri\u015fim: 75'ten fazla \u00fclkede operasyonlar<\/li> <\/ul> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: AbbVie'nin Kuzey Chicago genel merkezi, bilim insanlar\u0131n\u0131n nanoteknoloji kullanarak %95 do\u011frulukla belirli h\u00fccreleri hedefleyen yenilik\u00e7i bir ila\u00e7 ta\u015f\u0131ma sistemi geli\u015ftirdi\u011fi son teknoloji bir ara\u015ft\u0131rma tesisine ev sahipli\u011fi yap\u0131yor\u2014ila\u00e7lar\u0131n insan v\u00fccudu ile etkile\u015fim \u015feklini devrim niteli\u011finde de\u011fi\u015ftiriyor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AbbVie Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla, AbbVie Inc. (ABBV) New York Borsas\u0131&#8217;nda <strong>206,57 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>29 Ekim 2025<\/strong> kesinlikle kritik bir tarih\u2014AbbVie&#8217;nin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketleri yarat\u0131r ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bundan faydalanabilir.<\/p>\n<p><strong>Kazan\u00e7 Raporlar\u0131 ABBV Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>31 Temmuz 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>208,40 $<\/td>\n<td>%3,2 Art\u0131\u015f (1 hafta)<\/td>\n<\/tr>\n<tr>\n<td>25 Nisan 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>195,80 $<\/td>\n<td>%6,8 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>31 Ocak 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>182,50 $<\/td>\n<td>%7,1 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td>\n<\/tr>\n<tr>\n<td>29 Ekim 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>175,20 $<\/td>\n<td>%2,3 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7t\u0131)<\/td>\n<\/tr>\n<tr>\n<td>26 Temmuz 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>168,90 $<\/td>\n<td>%4,9 Art\u0131\u015f (Skyrizi patlamas\u0131)<\/td>\n<\/tr>\n<tr>\n<td>26 Nisan 2024<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>162,10 $<\/td>\n<td>%3,8 Art\u0131\u015f (istikrarl\u0131 b\u00fcy\u00fcme)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Temmuz 2025 gibi pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 birka\u00e7 g\u00fcn i\u00e7inde %3-7 oran\u0131nda art\u0131r\u0131r. Negatif sonu\u00e7lar bile, AbbVie&#8217;nin g\u00fc\u00e7l\u00fc temelleri sayesinde h\u0131zl\u0131 toparlanma f\u0131rsatlar\u0131 yarat\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2>\n<p>AbbVie hisseleri genel olarak yukar\u0131 y\u00f6nl\u00fc etkileyici bir diren\u00e7 g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 249 $ (k\u0131\u015f sonras\u0131 toparlanma +%6,9)<\/li>\n<li><strong>Nisan 2025<\/strong>: 263 $ (1. \u00e7eyrek kazan\u00e7 ivmesi +%5,6)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 268 $ (\u00fcretim geni\u015fleme haberi +%1,9)<\/li>\n<li><strong>Haziran 2025<\/strong>: 280 $ (pipeline geli\u015fmeleri +%4,5)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 316 $ (2. \u00e7eyrek kazan\u00e7 patlamas\u0131 +%12,9)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 276 $ (kar realizasyonu d\u00fczeltmesi -%12,7)<\/li>\n<\/ul>\n<p><strong>Bu ola\u011fan\u00fcst\u00fc performans\u0131n sebebi nedir?<\/strong> Skyrizi ve Rinvoq, 2025 1. \u00e7eyre\u011finde toplam 5,1 milyar $ sat\u0131\u015f ger\u00e7ekle\u015ftirdi\u2014y\u0131ll\u0131k %65 b\u00fcy\u00fcme. \u015eirketin stratejik 195 milyon $ \u00fcretim yat\u0131r\u0131m\u0131 ve ba\u015far\u0131l\u0131 klinik deneme sonu\u00e7lar\u0131 bu d\u00f6nemde yat\u0131r\u0131mc\u0131 g\u00fcvenini s\u00fcrd\u00fcr\u00fclebilir k\u0131ld\u0131.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 215-250 $ (g\u00fc\u00e7l\u00fc tatil \u00e7eyre\u011fi + pipeline kilometre ta\u015flar\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n<li><strong>2026 Projeksiyonu<\/strong>: 230-270 $ (uluslararas\u0131 geni\u015fleme + yeni endikasyonlar)<\/li>\n<li><strong>2028 Hedefi<\/strong>: 270-310 $ (terap\u00f6tik alan hakimiyeti + pazar pay\u0131 kazan\u0131mlar\u0131)<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 310-370 $ (k\u00fcresel sa\u011fl\u0131k b\u00fcy\u00fcmesi + yenilik liderli\u011fi)<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: <strong>Uzun vadeli birikim<\/strong> i\u00e7in ideal. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar 29 Ekim civar\u0131ndaki kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri izlemeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Humira Biyobenzeri Bask\u0131s\u0131<\/strong>: Patent korumas\u0131n\u0131n sona ermesiyle 2024 ba\u015f\u0131nda sat\u0131\u015flar %41 d\u00fc\u015ft\u00fc (<a href=\"https:\/\/monexa.ai\/blog\/abbvie-abbv-acquisition-expenses-humira-challenges-ABBV-2025-04-04\">Rekabet Etkisi<\/a>)<\/li>\n<li><strong>Reg\u00fclasyon Zorluklar\u0131<\/strong>: 2025 2. \u00e7eyrekte 29 finansal ve kurumsal risk tespit edildi, Ar-Ge belirsizlikleri ve uluslararas\u0131 operasyon karma\u015f\u0131kl\u0131klar\u0131 dahil<\/li>\n<li><strong>D\u00f6viz Dalgalanmas\u0131<\/strong>: Gelirin %24&#8217;\u00fc ABD d\u0131\u015f\u0131ndan geliyor, bu da k\u00e2rlar\u0131 d\u00f6viz kuru dalgalanmalar\u0131na kar\u015f\u0131 hassas k\u0131l\u0131yor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Skyrizi\/Rinvoq Roket Yak\u0131t\u0131<\/strong>: 2025&#8217;te 24,7 milyar $ ve 2027&#8217;de 31 milyar $ sat\u0131\u015f bekleniyor (<a href=\"https:\/\/www.nasdaq.com\/articles\/abbvie-stock-down-around-13-3-months-time-buy-dip\">B\u00fcy\u00fcme Projeksiyonlar\u0131<\/a>)<\/li>\n<li><strong>\u00dcretim Geni\u015flemesi<\/strong>: API \u00fcretim kapasitesini art\u0131ran 195 milyon $ yat\u0131r\u0131m (<a href=\"https:\/\/www.ainvest.com\/news\/abbvie-195m-illinois-expansion-drives-10b-investment-plan-182nd-tier-trading-volume-2508\/\">Stratejik Yat\u0131r\u0131m<\/a>)<\/li>\n<li><strong>Klinik At\u0131l\u0131mlar<\/strong>: Faz 3 denemesi kanser ilerleme riskini %79 azaltt\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ul>\n<li><strong>Stratejik Birikim<\/strong>: Haftal\u0131k sadece 100 $ gibi k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n\u2014zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in dolar maliyeti ortalamas\u0131 kullan\u0131n<\/li>\n<li><strong>Kazan\u00e7 Takibi<\/strong>: 29 Ekim kazan\u00e7lar\u0131 i\u00e7in uyar\u0131lar kurun; a\u00e7\u0131klama sonras\u0131 hisse %3-5 d\u00fc\u015ferse almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Portf\u00f6y Dengesi<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn maksimum %8-10&#8217;unu ABBV gibi ila\u00e7 hisselerine ay\u0131r\u0131n<\/li>\n<li><strong>Esprili deneyimli tavsiyesi<\/strong>: &#8220;ABBV ticareti, ila\u00e7 Ar-Ge&#8217;si gibidir\u2014bazen uzun vadeli sa\u011fl\u0131k faydalar\u0131 i\u00e7in k\u0131sa vadeli yan etkileri g\u00f6ze almal\u0131s\u0131n\u0131z. Piyasay\u0131 deneysel ila\u00e7 al\u0131r gibi zamanlamaya \u00e7al\u0131\u015fmay\u0131n!&#8221;<\/li>\n<\/ul>\n<h2>\u2705 AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ticaret platformu se\u00e7in<\/td>\n<td>NYSE eri\u015fimi ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014k\u0131smi hisseler i\u00e7in 50 $ bile yeterli<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ABBV&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>Sadece &#8220;AbbVie&#8221; de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emri: \u00d6deyece\u011finiz maksimum fiyat\u0131 belirleyin (\u00f6rne\u011fin 208 $)<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td>\n<td>Komisyon maliyetlerini g\u00f6zden ge\u00e7irin\u2014i\u015flem \u00fccretlerinin %0,5&#8217;in alt\u0131nda olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Kazan\u00e7 tarihleri ve \u00f6nemli haberler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Temett\u00fcleri yeniden yat\u0131r\u0131n<\/td>\n<td>ABBV y\u0131lda 6,56 $ \u00f6der\u2014bile\u015fik getiri i\u00e7in DRIP&#8217;i etkinle\u015ftirin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7eyrek d\u00f6nemlerde g\u00f6zden ge\u00e7irin<\/td>\n<td>Performans\u0131 ila\u00e7 sekt\u00f6r\u00fc k\u0131yaslamalar\u0131na kar\u015f\u0131 de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in borsa eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri neredeyse hi\u00e7 finansal risk olmadan test edin<\/li>\n<li><strong>60 saniyede do\u011frulama<\/strong>\u2014herhangi bir resmi kimlik y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li>\n<li><strong>100&#8217;den fazla para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para, e-c\u00fczdanlar, banka transferleri, kredi kartlar\u0131<\/li>\n<li><strong>K\u0131smi hisse al\u0131m\u0131 m\u00fcmk\u00fcn<\/strong>\u2014ABBV gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 k\u00fc\u00e7\u00fck miktarlarla sat\u0131n al\u0131n<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014profesyonel grafikler ve analiz ara\u00e7lar\u0131na eri\u015fim<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, <strong>AbbVie Inc. (ABBV) hisse senedi yat\u0131r\u0131m\u0131n\u0131z\u0131<\/strong> kolayca ger\u00e7ekle\u015ftirmenizi sa\u011flarken, e\u011fitim kaynaklar\u0131 ila\u00e7 sekt\u00f6r\u00fc dinamiklerini anlaman\u0131za yard\u0131mc\u0131 olur.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te AbbVie: \u0130la\u00e7 Devi D\u00f6n\u00fc\u015f\u00fcm\u00fc<\/h2>\n<p>AbbVie, Humira sonras\u0131 d\u00f6nemde ba\u011f\u0131\u015f\u0131kl\u0131k ve onkoloji pazarlar\u0131nda etkileyici bir d\u00f6n\u00fc\u015f\u00fcm hikayesiyle hakimiyet kuruyor. \u015eirket, bir\u00e7ok ila\u00e7 devini bat\u0131ran patent u\u00e7urumunu ba\u015far\u0131yla atlatt\u0131 ve 2025 2. \u00e7eyre\u011finde 15,42 milyar $ gelir elde eden \u00e7e\u015fitlendirilmi\u015f bir portf\u00f6yle g\u00fc\u00e7lenerek \u00e7\u0131kt\u0131.<\/p>\n<p><strong>Mevcut Pazar Konumu<\/strong>:<\/p>\n<ul>\n<li>Piyasa de\u011feri: 365,13 milyar $<\/li>\n<li>Temett\u00fc aristokrat\u0131: 11 y\u0131l \u00fcst \u00fcste art\u0131\u015f<\/li>\n<li>Ba\u011f\u0131\u015f\u0131kl\u0131k lideri: Skyrizi ile biyolojik sedef hastal\u0131\u011f\u0131 pazar\u0131nda %40 pay<\/li>\n<li>K\u00fcresel eri\u015fim: 75&#8217;ten fazla \u00fclkede operasyonlar<\/li>\n<\/ul>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: AbbVie&#8217;nin Kuzey Chicago genel merkezi, bilim insanlar\u0131n\u0131n nanoteknoloji kullanarak %95 do\u011frulukla belirli h\u00fccreleri hedefleyen yenilik\u00e7i bir ila\u00e7 ta\u015f\u0131ma sistemi geli\u015ftirdi\u011fi son teknoloji bir ara\u015ft\u0131rma tesisine ev sahipli\u011fi yap\u0131yor\u2014ila\u00e7lar\u0131n insan v\u00fccudu ile etkile\u015fim \u015feklini devrim niteli\u011finde de\u011fi\u015ftiriyor!<\/p>\n"},"faq":[{"question":"AbbVie hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum veya online ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ABBV\" sembol\u00fcn\u00fc aray\u0131n, limit veya piyasa emri verin ve sat\u0131n alma i\u015flemini tamamlay\u0131n."},{"question":"AbbVie'nin 2025 i\u00e7in fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in AbbVie hisseleri 215-250 $ aral\u0131\u011f\u0131nda tahmin edilmekte olup, g\u00fc\u00e7l\u00fc bir sat\u0131n alma \u00f6nerisi bulunmaktad\u0131r."},{"question":"AbbVie hisseleri i\u00e7in temel riskler nelerdir?","answer":"Humira biyobenzeri rekabeti, reg\u00fclasyon zorluklar\u0131 ve d\u00f6viz kuru dalgalanmalar\u0131 ba\u015fl\u0131ca riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar AbbVie hisseleri i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, kazan\u00e7 tarihlerini takip etmeli ve portf\u00f6yde %8-10 aras\u0131 ila\u00e7 hissesi bulundurmal\u0131d\u0131r."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi, k\u0131smi hisse al\u0131m\u0131 ve ger\u00e7ek zamanl\u0131 piyasa verisi sunmas\u0131 nedeniyle yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"AbbVie hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum veya online ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ABBV\" sembol\u00fcn\u00fc aray\u0131n, limit veya piyasa emri verin ve sat\u0131n alma i\u015flemini tamamlay\u0131n."},{"question":"AbbVie'nin 2025 i\u00e7in fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in AbbVie hisseleri 215-250 $ aral\u0131\u011f\u0131nda tahmin edilmekte olup, g\u00fc\u00e7l\u00fc bir sat\u0131n alma \u00f6nerisi bulunmaktad\u0131r."},{"question":"AbbVie hisseleri i\u00e7in temel riskler nelerdir?","answer":"Humira biyobenzeri rekabeti, reg\u00fclasyon zorluklar\u0131 ve d\u00f6viz kuru dalgalanmalar\u0131 ba\u015fl\u0131ca riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar AbbVie hisseleri i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, kazan\u00e7 tarihlerini takip etmeli ve portf\u00f6yde %8-10 aras\u0131 ila\u00e7 hissesi bulundurmal\u0131d\u0131r."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi, k\u0131smi hisse al\u0131m\u0131 ve ger\u00e7ek zamanl\u0131 piyasa verisi sunmas\u0131 nedeniyle yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:11:03+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T13:11:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\",\"name\":\"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-19T13:11:03+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/","og_locale":"tr_TR","og_type":"article","og_title":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:11:03+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T13:11:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/","name":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-19T13:11:03+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":337913,"slug":"how-to-buy-abbvie","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AbbVie Inc. (ABBV) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-abbvie\/"},"pt_AA":{"locale":"pt_AA","id":337915,"slug":"how-to-buy-abbvie","post_title":"Como comprar a\u00e7\u00f5es da AbbVie Inc. (ABBV) - Investimento em a\u00e7\u00f5es da AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-abbvie\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=337912"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337912\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=337912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=337912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=337912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}